Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment.
Seven of nine depressed patients experienced a 4.3-fold increase in rated euphoria and activation following 30 mg d-amphetamine in a replicated dose, double blind study. d-Amphetamine was 2 to 2.3-fold more effective in producing activation, euphoria, and antidepressant effects than the same dose of l-amphetamine. Co-treatment with lithium carbonate produced a 60% (P less than 0.001) attenuation of the activation and euphoria responses to d-amphetamine. The responses to l-amphetamine were almost completely abolished by lithium. This study raises the possibility of lithium carbonate use as an adjunct in the treatment of amphetamine addiction.
D000328:Adult; D000661:Amphetamine / Q000037:antagonists & inhibitors* / Q000097:blood / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy*; D003913:Dextroamphetamine / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D005059:Euphoria / Q000187:drug effects*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008094:Lithium / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012647:Self-Assessment; D013237:Stereoisomerism; D014556:Urine
D010919:Placebos; D008094:Lithium; D000661:Amphetamine; D003913:Dextroamphetamine